Portraying G protein-coupled receptors with fluorescent ligands

ACS Chemical Biology

Volumn 9, Issue 9, 2014, Pages 1918-1928

  Ciruela, Francisco ^a   Jacobson, Kenneth A ^b   Fernández Dueñas, Víctor ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

^b NATIONAL INSTITUTE OF DIABETES AND DIGESTIVE AND KIDNEY DISEASES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

G PROTEIN COUPLED RECEPTOR; LIGAND; FLUORESCENT DYE;

CELL MEMBRANE; CELL SURFACE; CELLULAR DISTRIBUTION; DRUG DEVELOPMENT; FLUORESCENCE RESONANCE ENERGY TRANSFER; HIGH THROUGHPUT SCREENING; HUMAN; LIGAND BINDING; MOLECULAR INTERACTION; OLIGOMERIZATION; PHARMACOPHORE; RECEPTOR BINDING; RECEPTOR BINDING ASSAY; REVIEW; STRUCTURE ACTIVITY RELATION; THERMODYNAMICS; CHEMISTRY; METABOLISM; PROCEDURES; SYNTHESIS;

CELL MEMBRANE; DRUG DISCOVERY; FLUORESCENCE RESONANCE ENERGY TRANSFER; FLUORESCENT DYES; HUMANS; LIGANDS; RECEPTORS, G-PROTEIN-COUPLED;

EID: 84912544840     PISSN: 15548929     EISSN: 15548937     Source Type: Journal    
DOI: 10.1021/cb5004042     Document Type: Review

References (99)

1. Lefkowitz, R. J. (2000) The superfamily of heptahelical receptors. Nat. Cell Biol. 2, E133-6.
2. Gilman, A. G. (1987) G proteins: Transducers of receptor-generated signals. Annu. Rev. Biochem. 56, 615-649.
3. Wettschureck, N., and Offermanns, S. (2005) Mammalian G proteins and their cell type specific functions. Physiol. Rev. 85, 1159-1204.
4. Ritter, S. L., and Hall, R. A. (2009) Fine-tuning of GPCR activity by receptor-interacting proteins. Nat. Rev. Cell Biol. 10, 819-830.
5. Ciruela, F., Vilardaga, J.-P., and Fernández-Dueñas, V. (2010) Lighting up multiprotein complexes: Lessons from GPCR oligomerization. Trends Biotechnol. 28, 407-415.
6. Cottet, M., Faklaris, O., Maurel, D., Scholler, P., Doumazane, E., Trinquet, E., Pin, J. P., and Durroux, T. (2012) BRET and time-resolved FRET strategy to study GPCR oligomerization: From cell lines toward native tissues. Front. Endocrinol. (Lausanne) 3, 92.
7. Zwier, J. M., Roux, T., Cottet, M., Durroux, T., Douzon, S., Bdioui, S., Gregor, N., Bourrier, E., Oueslati, N., Nicolas, L., Tinel, N., Boisseau, C., Yverneau, P., Charrier-Savournin, F., Fink, M., and Trinquet, E. (2010) A fluorescent ligand-binding alternative using Tag-lite(R) technology. J. Biomol. Screening 15, 1248-1259.
8. McGrath, J. C., Arribas, S., and Daly, C. J. (1996) Fluorescent ligands for the study of receptors. Trends Pharmacol. Sci. 17, 393-399.
9. Kozma, E., Jayasekara, P. S., Squarcialupi, L., Paoletta, S., Moro, S., Federico, S., Spalluto, G., and Jacobson, K. A. (2013) Fluorescent ligands for adenosine receptors. Bioorg. Med. Chem. Lett. 23, 26-36.
10. Vernall, A. J., Hill, S. J., and Kellam, B. (2013) The evolving small-molecule fluorescent-conjugate toolbox for class A GPCRs. Br. J. Pharmacol. 171, 1073-84.
11. Waggoner, A. (2006) Fluorescent labels for proteomics and genomics. Curr. Opin. Chem. Biol. 10, 62-66.
12. Lavis, L. D., and Raines, R. T. (2014) Bright building blocks for chemical biology. ACS Chem. Biol. 9, 855-866.
13. Madsen, B. W., Beglan, C. L., and Spivak, C. E. (2000) Fluorescein-labeled naloxone binding to mu opioid receptors on live Chinese hamster ovary cells using confocal fluorescent microscopy. J. Neurosci. Methods 97, 123-131.
14. Pick, H., Preuss, A. K., Mayer, M., Wohland, T., Hovius, R., and Vogel, H. (2003) Monitoring expression and clustering of the ionotropic 5HT3 receptor in plasma membranes of live biological cells. Biochemistry 42, 877-884.
15. Tahtaoui, C., Parrot, I., Klotz, P., Guillier, F., Galzi, J. L., Hibert, M., and Ilien, B. (2004) Fluorescent pirenzepine derivatives as potential bitopic ligands of the human M1 muscarinic receptor. J. Med. Chem. 47, 4300-4315.
16. Fabry, M., Cabrele, C., Hocker, H., and Beck-Sickinger, A. G. (2000) Differently labeled peptide ligands for rapid investigation of receptor expression on a new human glioblastoma cell line. Peptides 21, 1885-1893.
17. Hegener, O., Prenner, L., Runkel, F., Baader, S. L., Kappler, J., and Haberlein, H. (2004) Dynamics of β2-adrenergic receptor-ligand complexes on living cells. Biochemistry 43, 6190-6199.
18. Strong, A. E., Thierry, A. C., Cousin, P., Moulon, C., and Demotz, S. (2006) Synthetic chemokines directly labeled with a fluorescent dye as tools for studying chemokine and chemokine receptor interactions. Eur. Cytokine Netw. 17, 49-59.
19. Rao, J., Dragulescu-Andrasi, A., and Yao, H. (2007) Fluorescence imaging in vivo: Recent advances. Curr. Opin. Biotechnol. 18, 17-25.
20. Bohme, I., and Beck-Sickinger, A. G. (2009) Illuminating the life of GPCRs. Cell Commun. Signal 7, 16.
21. Yildiz, I., Tomasulo, M., and Raymo, F. M. (2006) A mechanism to signal receptor-substrate interactions with luminescent quantum dots. Proc. Natl. Acad. Sci. U.S.A. 103, 11457-11460.
22. Resch-Genger, U., Grabolle, M., Cavaliere-Jaricot, S., Nitschke, R., and Nann, T. (2008) Quantum dots versus organic dyes as fluorescent labels. Nat. Methods 5, 763-75.
23. Lutz, W. H., Londowski, J. M., and Kumar, R. (1990) The synthesis and biological activity of four novel fluorescent vasopressin analogs. J. Biol. Chem. 265, 4657-4663.
24. Lutz, W., Sanders, M., Salisbury, J., Lolait, S., O'Carroll, A. M., and Kumar, R. (1993) Vasopressin receptor-mediated endocytosis in cells transfected with V1-type vasopressin receptors. Kidney Int. 43, 845-852.
25. Turcatti, G., Nemeth, K., Edgerton, M. D., Knowles, J., Vogel, H., and Chollet, A. (1997) Fluorescent labeling of NK2 receptor at specific sites in vivo and fluorescence energy transfer analysis of NK2 ligand-receptor complexes. Receptors Channels 5, 201-7.
26. Schneider, E., Keller, M., Brennauer, A., Hoefelschweiger, B. K., Gross, D., Wolfbeis, O. S., Bernhardt, G., and Buschauer, A. (2007) Synthesis and characterization of the first fluorescent nonpeptide NPY Y1 receptor antagonist. ChemBioChem 8, 1981-1988.
27. Briddon, S. J., Kellam, B., and Hill, S. J. (2011) Design and use of fluorescent ligands to study ligand-receptor interactions in single living cells. Methods Mol. Biol. 746, 211-236.
28. Cottet, M., Faklaris, O., Falco, A., Trinquet, E., Pin, J. P., Mouillac, B., and Durroux, T. (2013) Fluorescent ligands to investigate GPCR binding properties and oligomerization. Biochem. Soc. Trans. 41, 148-153.
29. Hemmilä, I., Dakubu, S., Mukkala, V. M., Siitari, H., and Lövgren, T. (1984) Europium as a label in time-resolved immunofluorometric assays. Anal. Biochem. 137, 335-43.
30. Handl, H. L., Vagner, J., Yamamura, H. I., Hruby, V. J., and Gillies, R. J. (2005) Development of a lanthanide-based assay for detection of receptor -ligand interactions at the δ-opioid receptor. Anal. Biochem. 343, 299-307.
31. Zuck, P., Lao, Z., Skwish, S., Glickman, J. F., Yang, K., Burbaum, J., and Inglese, J. (1999) Ligand-receptor binding measured by laser-scanning imaging. Proc. Natl. Acad. Sci. U. S.A. 96, 11122-11127.
32. Dietz, L. J., Dubrow, R. S., Manian, B. S., and Sizto, N. L. (1996) Volumetric capillary cytometry: A new method for absolute cell enumeration. Cytometry 23, 177-186.
33. Parker, G. J., Law, T. L., Lenoch, F. J., and Bolger, R. E. (2000) Development of high throughput screening assays using fluorescence polarization: nuclear receptor-ligand-binding and kinase/phosphatase assays. J. Biomol. Screening 5, 77-88.
34. Allen, M., Reeves, J., and Mellor, G. (2000) High throughput fluorescence polarization: A homogeneous alternative to radioligand binding for cell surface receptors. J. Biomol. Screening 5, 63-69.
35. Daly, C. J., Ross, R. A., Whyte, J., Henstridge, C. M., Irving, A. J., and McGrath, J. C. (2010) Fluorescent ligand binding reveals heterogeneous distribution of adrenoceptors and "cannabinoid-like" receptors in small arteries. Br. J. Pharmacol. 159, 787-796.
36. May, L. T., Self, T. J., Briddon, S. J., and Hill, S. J. (2010) The effect of allosteric modulators on the kinetics of agonist-G protein-coupled receptor interactions in single living cells. Mol. Pharmacol. 78, 511-523.
37. Stoddart, L. A., Vernall, A. J., Denman, J. L., Briddon, S. J., Kellam, B., and Hill, S. J. (2012) Fragment screening at adenosine-A(3) receptors in living cells using a fluorescence-based binding assay. Chem. Biol. 19, 1105-1115.
38. Hopkins, A. L., Groom, C. R., and Alex, A. (2004) Ligand efficiency: A useful metric for lead selection. Drug Discovery Today 9, 430-431.
39. Ilien, B., Franchet, C., Bernard, P., Morisset, S., Weill, C. O., Bourguignon, J. J., Hibert, M., and Galzi, J. L. (2003) Fluorescence resonance energy transfer to probe human M1 muscarinic receptor structure and drug binding properties. J. Neurochem. 85, 768-778.
40. Fernandez-Duenas, V., Gomez-Soler, M., Jacobson, K. A., Kumar, S. T., Fuxe, K., Borroto-Escuela, D. O., and Ciruela, F. (2012) Molecular determinants of A(2A) R-D(2) R allosterism: Role of the intracellular loop 3 of the D(2) R. J. Neurochem. 123, 373-384.
41. Sun, X., Zhang, A., Baker, B., Sun, L., Howard, A., Buswell, J., Maurel, D., Masharina, A., Johnsson, K., Noren, C. J., Xu, M. Q., and Correa, I. R., Jr. (2011) Development of SNAP-tag fluorogenic probes for wash-free fluorescence imaging. ChemBioChem 12, 2217-2226.
42. Gautier, A., Juillerat, A., Heinis, C., Correa, I. R., Jr., Kindermann, M., Beaufils, F., and Johnsson, K. (2008) An engineered protein tag for multiprotein labeling in living cells. Chem. Biol. 15, 128-136.
43. Keppler, A., Gendreizig, S., Gronemeyer, T., Pick, H., Vogel, H., and Johnsson, K. (2003) A general method for the covalent labeling of fusion proteins with small molecules in vivo. Nat. Biotechnol. 21, 86-89.
44. Keppler, A., Kindermann, M., Gendreizig, S., Pick, H., Vogel, H., and Johnsson, K. (2004) Labeling of fusion proteins of O6-alkylguanine-DNA alkyltransferase with small molecules in vivo and in vitro. Methods 32, 437-444.
45. Keppler, A., Pick, H., Arrivoli, C., Vogel, H., and Johnsson, K. (2004) Labeling of fusion proteins with synthetic fluorophores in live cells. Proc. Natl. Acad. Sci. U.S.A. 101, 9955-9959.
46. Mathis, G. (1993) Rare earth cryptates and homogeneous fluoroimmunoassays with human sera. Clin. Chem. 39, 1953-1959.
47. Mathis, G. (1995) Probing molecular interactions with homogeneous techniques based on rare earth cryptates and fluorescence energy transfer. Clin. Chem. 41, 1391-1397.
48. Bazin, H., Preaudat, M., Trinquet, E., and Mathis, G. (2001) Homogeneous time resolved fluorescence resonance energy transfer using rare earth cryptates as a tool for probing molecular interactions in biology. Spectrochim. Acta Part A, Mol. Biomol. Spectrosc. 57, 2197-2211.
49. Bazin, H., Trinquet, E., and Mathis, G. (2002) Time resolved amplification of cryptate emission: A versatile technology to trace biomolecular interactions. J. Biotechnol. 82, 233-250.
50. Terrillon, S., Durroux, T., Mouillac, B., Breit, A., Ayoub, M. A., Taulan, M., Jockers, R., Barberis, C., and Bouvier, M. (2003) Oxytocin and vasopressin V1a and V2 receptors form constitutive homo- and heterodimers during biosynthesis. Mol. Endocrinol. 17, 677-691.
51. Cottet, M., Albizu, L., Comps-Agrar, L., Trinquet, E., Pin, J. P., Mouillac, B., and Durroux, T. (2011) Time resolved FRET strategy with fluorescent ligands to analyze receptor interactions in native tissues: application to GPCR oligomerization. Methods Mol. Biol. 746, 373-387.
52. Albizu, L., Teppaz, G., Seyer, R., Bazin, H., Ansanay, H., Manning, M., Mouillac, B., and Durroux, T. (2007) Toward efficient drug screening by homogeneous assays based on the development of new fluorescent vasopressin and oxytocin receptor ligands. J. Med. Chem. 50, 4976-4985.
53. Maurel, D., Kniazeff, J., Mathis, G., Trinquet, E., Pin, J. P., and Ansanay, H. (2004) Cell surface detection of membrane protein interaction with homogeneous time-resolved fluorescence resonance energy transfer technology. Anal. Biochem. 329, 253-262.
54. Tahtaoui, C., Guillier, F., Klotz, P., Galzi, J.-L., Hibert, M., and Ilien, B. (2005) On the use of nonfluorescent dye labeled ligands in FRET-based receptor binding studies. J. Med. Chem. 48, 7847-59.
55. Kopra, K., Shweta, Martikkala, E., Hänninen, P., Petäjä-Repo, U., and Härmä, H. (2013) A homogeneous single-label quenching resonance energy transfer assay for a δ-opioid receptor-ligand using intact cells. Analyst 138, 4907-14.
56. Patel, R. C., Kumar, U., Lamb, D. C., Eid, J. S., Rocheville, M., Grant, M., Rani, A., Hazlett, T., Patel, S. C., Gratton, E., and Patel, Y. C. (2002) Ligand binding to somatostatin receptors induces receptor-specific oligomer formation in live cells. Proc. Natl. Acad. Sci. U.S.A. 99, 3294-3299.
57. Hern, J. A., Baig, A. H., Mashanov, G. I., Birdsall, B., Corrie, J. E., Lazareno, S., Molloy, J. E., and Birdsall, N. J. (2010) Formation and dissociation of M1 muscarinic receptor dimers seen by total internal reflection fluorescence imaging of single molecules. Proc. Natl. Acad. Sci. U.S.A. 107, 2693-2698.
58. Maurel, D., Comps-Agrar, L., Brock, C., Rives, M. L., Bourrier, E., Ayoub, M. A., Bazin, H., Tinel, N., Durroux, T., Prezeau, L., Trinquet, E., and Pin, J. P. (2008) Cell-surface protein-protein interaction analysis with time-resolved FRET and SNAP-tag technologies: Application to GPCR oligomerization. Nat. Methods 5, 561-567.
59. Kern, A., Albarran-Zeckler, R., Walsh, H. E., and Smith, R. G. (2012) Apo-ghrelin receptor forms heteromers with DRD2 in hypothalamic neurons and is essential for anorexigenic effects of DRD2 agonism. Neuron 73, 317-332.
60. Albizu, L., Cottet, M., Kralikova, M., Stoev, S., Seyer, R., Brabet, I., Roux, T., Bazin, H., Bourrier, E., Lamarque, L., Breton, C., Rives, M. L., Newman, A., Javitch, J., Trinquet, E., Manning, M., Pin, J. P., Mouillac, B., and Durroux, T. (2010) Time-resolved FRET between GPCR ligands reveals oligomers in native tissues. Nat. Chem. Biol. 6, 587-594.
61. Durroux, T. (2005) Principles: A model for the allosteric interactions between ligand binding sites within a dimeric GPCR. Trends Pharmacol. Sci. 26, 376-384.
62. Rovira, X., Pin, J. P., and Giraldo, J. (2010) The asymmetric/ symmetric activation of GPCR dimers as a possible mechanistic rationale for multiple signalling pathways. Trends Pharmacol. Sci. 31, 15-21.
63. Fernandez-Duenas, V., Gomez-Soler, M., Morato, X., Nunez, F., Das, A., Kumar, T. S., Jauma, S., Jacobson, K. A., and Ciruela, F. (2013) Dopamine D2 receptor-mediated modulation of adenosine A2A receptor agonist binding within the A2AR/D2R oligomer framework. Neurochem. Int. 63, 42-46.
64. Fribourg, M., Moreno, J. L., Holloway, T., Provasi, D., Baki, L., Mahajan, R., Park, G., Adney, S. K., Hatcher, C., Eltit, J. M., Ruta, J. D., Albizu, L., Li, Z., Umali, A., Shim, J., Fabiato, A., MacKerell, A. D., Jr., Brezina, V., Sealfon, S. C., Filizola, M., Gonzalez-Maeso, J., and Logothetis, D. E. (2011) Decoding the signaling of a GPCR heteromeric complex reveals a unifying mechanism of action of antipsychotic drugs. Cell 147, 1011-1023.
65. Cardullo, R. A. (2007) Theoretical principles and practical considerations for fluorescence resonance energy transfer microscopy. Methods Cell Biol. 81, 479-494.
66. Förster, T. (1948) Zwischenmolekulare energiewanderung und fluoreszenz. Ann. Phys. 2, 55-75.
67. Stryer, L., and Haugland, R. P. (1967) Energy transfer: A spectroscopic ruler. Proc. Natl. Acad. Sci. U.S.A. 58, 719-726.
68. Piston, D. W., and Kremers, G. J. (2007) Fluorescent protein FRET: The good, the bad, and the ugly. Trends Biochem. Sci. 32, 407-414.
69. James, J. R., Oliveira, M. I., Carmo, A. M., Iaboni, A., and Davis, S. J. (2006) A rigorous experimental framework for detecting protein oligomerization using bioluminescence resonance energy transfer. Nat. Methods 3, 1001-1006.
70. Bouvier, M., Heveker, N., Jockers, R., Marullo, S., and Milligan, G. (2007) BRET analysis of GPCR oligomerization: Newer does not mean better. Nat. Methods 4, 3-4.
71. Varani, K., Portaluppi, F., Gessi, S., Merighi, S., Ongini, E., Belardinelli, L., and Borea, P. A. (2009) Dose and time effects of caffeine intake on human platelet adenosine A(2A) receptors: Functional and biochemical aspects. Circulation 102, 285-9.
72. Carroll, M. A., Doumad, A. B., Li, J., Cheng, M. K., Falck, J. R., and McGiff, J. C. (2006) Adenosine2A receptor vasodilation of rat preglomerular microvessels is mediated by EETs that activate the cAMP/PKA pathway. Am. J. Physiol. Renal Physiol. 291, F155-61.
73. Popoli, P., Betto, P., Reggio, R., and Ricciarello, G. (199) Adenosine A2A receptor stimulation enhances striatal extracellular glutamate levels in rats. Eur. J. Pharmacol. 287, 215-7.
74. Nagel, J., Schladebach, H., Koch, M., Schwienbacher, I., and Müller, C. E. (2003) Effects of an adenosine A2A receptor blockade in the nucleus accumbens on locomotion, feeding, and prepulse inhibition in rats. Synapse 49, 279-86.
75. Scammell, T. E., Gerashchenko, D. Y., Mochizuiki, T., McCarthy, M. T., Estabrooke, I. V., Sears, C. A., Scaper, C. B., Urade, Y., and Hayaishi, O. (2001) An adenosine A2a agonist increases sleep and induces Fos in ventrolateral preoptic neurons. Neuroscience 107, 653-63.
76. Zhong, H., Shlykov, S. G., Molina, J. G., Sanborn, B. M., Jacobson, M. A., Tilley, S. L., and Blackburn, M. R. (2003) Activation of murine lung mast cells by the adenosine A3 receptor. J. Immunol. 171, 338-45.
77. Das, S., Cordis, G. A., Maulik, N., and Das, D. K. (2005) Pharmacological preconditioning with resveratrol: role of CREB-dependent Bcl-2 signaling via adenosine A3 receptor activation. Am. J. Physiol. Heart Circ. Physiol. 288, H328-35.
78. Hinschen, A. K., Rose'Meyer, R. B., and Headrick, J. P. (2003) Adenosine receptor subtypes mediating coronary vasodilation in rat hearts. J. Cardiovasc. Pharmacol. 41, 73-80.
79. Avila, M. Y., Stone, R. A., and Civan, M. M. (2002) Knockout of A3 adenosine receptors reduces mouse intraocular pressure. Invest. Ophthalmol. Vis. Sci. 43, 3021-6.
80. Stella, L., de Novellis, V., Marabese, I., Berrino, L., Maione, S., Filippelli, A., and Rossi, F. (1998) The role of A3 adenosine receptors in central regulation of arterial blood pressure. Br. J. Pharmacol. 125, 437-40.
81. Breese, G. R., Duncan, G. E., Napier, T. C., Bondy, S. C., Iorio, L. C., and Mueller, R. A. (1987) 6-hydroxydopamine treatments enhance behavioral responses to intracerebral microinjection of D1-and D2-dopamine agonists into nucleus accumbens and striatum without changing dopamine antagonist binding. J. Pharmacol. Exp. Ther. 240, 167-76.
82. Bughi, S., Jost-Vu, E., Antonipillai, I., Nadler, J., and Horton, R. (1994) Effect of dopamine2 blockade on renal function under varied sodium intake. J. Clin. Endocrinol. Metab. 78, 1079-84.
83. Setlow, B., and McGaugh, J. L. (2000) D2 dopamine receptor blockade immediately post-training enhances retention in hidden and visible platform versions of the water maze. Learn. Mem. 7, 187-91.
84. Pasternak, G. W. (1993) Pharmacological mechanisms of opioid analgesics. Clin. Neuropharmacol. 16, 1-18.
85. Boom, M., Niesters, M., Sarton, E., Aarts, L., Smith, T. W., and Dahan, A. (2012) Non-analgesic effects of opioids: Opioid-induced respiratory depression. Curr. Pharm. Des. 18, 5994-6004.
86. Marczak, E. D., Jinsmaa, Y., Myers, P. H., Blankenship, T., Wilson, R., Balboni, G., Salvadori, S., and Lazarus, L. H. (2009) Orally administered H-Dmt-Tic-Lys-NH-CH2-Ph (MZ-2), a potent μ/δ-opioid receptor antagonist, regulates obese-related factors in mice. Eur. J. Pharmacol. 616, 115-21.
87. Samways, D. S. K., and Henderson, G. (2006) Opioid elevation of intracellular free calcium: Possible mechanisms and physiological relevance. Cell. Signalling 18, 151-61.
88. Handler, C. M., Geller, E. B., and Adler, M. W. (1992) Effect of μ-, κ-, and δ-selective opioid agonists on thermoregulation in the rat. Pharmacol. Biochem. Behav. 43, 1209-16.
89. Lammers, J. W., Minette, P., McCusker, M., and Barnes, P. J. (1989) The role of pirenzepine-sensitive (M1) muscarinic receptors in vagally mediated bronchoconstriction in humans. Am. Rev. Respir. Dis. 139, 446-9.
90. Wilson, P. S., Khimenko, P. L., Barnard, J. W., Moore, T. M., and Taylor, A. E. (1995) Muscarinic agonists and antagonists cause vasodilation in isolated rat lung. J. Appl. Physiol. 78, 1404-11.
91. Messer, W. S., Bohnett, M., and Stibbe, J. (1990) Evidence for a preferential involvement of M1 muscarinic receptors in representational memory. Neurosci. Lett. 116, 184-9.
92. Sen, A. P., and Bhattacharya, S. K. (1991) Thermic response of selective muscarinic agonists and antagonists in rat. Indian J. Exp. Biol. 29, 131-5.
93. Polidori, C., Massi, M., Lambrecht, G., Mutschler, E., Tacke, R., and Melchiorre, C. (1990) Selective antagonists provide evidence that M1 muscarinic receptors may mediate carbachol-induced drinking in the rat. Eur. J. Pharmacol. 179, 159-65.
94. Kono, M., Nakamura, Y., Ishiura, Y., Komatsu, K., Kontani, H., and Namiki, M. (2006) Central muscarinic receptor subtypes regulating voiding in rats. J. Urol. 175, 353-7.
95. Wren, A. M., Seal, L. J., Cohen, M. A., Brynes, A. E., Frost, G. S., Murphy, K. G., Dhillo, W. S., Ghatei, M. A., and Bloom, S. R. (2001) Ghrelin enhances appetite and increases food intake in humans. J. Clin. Endocrinol. Metab. 86, 5992.
96. Takaya, K., Ariyasu, H., Kanamoto, N., Iwakura, H., Yoshimoto, A., Harada, M., Mori, K., Komatsu, Y., Usui, T., Shimatsu, A., Ogawa, Y., Hosoda, K., Akamizu, T., Kojima, M., Kangawa, K., and Nakao, K. (2000) Ghrelin strongly stimulates growth hormone release in humans. J. Clin. Endocrinol. Metab. 85, 4908-11.
97. Shi, W., Cui, N., Shi, Zhang, X., Yang, Y., and Jiang, C. (2007) Arginine vasopressin inhibits Kir6.1/SUR2B channel and constricts the mesenteric artery via V1a receptor and protein kinase C. Am. J. Physiol. Regul. Integr. Comp. Physiol. 293, R191-9.
98. Tachikawa, K., Yokoi, H., Nagasaki, H., Arima, H., Murase, T., Sugimura, Y., Miura, Y., Hirabayashi, M., and Oiso, Y. (2003) Altered cardiovascular regulation in arginine vasopressin-overexpressing transgenic rat. Am. J. Physiol. Endocrinol. Metab. 285, E1161-6.
99. Hasan, K. N., Shoji, M., Tsutaya, S., Kudo, R., Matsuda, E., Saito, J., Kimura, T., and Yasujima, M. (2006) Study of V1a vasopressin receptor gene single nucleotide polymorphisms in platelet vasopressin responsiveness. J. Clin. Lab. Anal. 20, 87-92.